Infection: Antibiotic treatment does not improve all-cause mortality and disease progression in patients with new coronavirus infection

Because in influenza and other respiratory virus infections , bacterial superinfection can lead to higher morbidity and mortality, prompt diagnosis and antibiotic treatment (ABT) are required
.

The use of antibiotics reported in the 2019 Coronavirus Disease ( COVID-19 ) is much higher than the actual ratio of bacterial co-infection and superinfection.

Because in influenza and other respiratory virus infections , bacterial superinfection can lead to higher morbidity and mortality, prompt diagnosis and antibiotic treatment (ABT) are required

 

Researchers included 6,457 SARS-CoV-2 infection cases in the LEOSS cohort between March 18, 2020 and February 16, 2021
.

For adult patients with procalcitonin (PCT) ≤ 0.

 

Finally, a total of 3627 patients met the inclusion criteria for the analysis
.

For the primary observation endpoint, the researchers found that antibiotic treatment was not associated with lower all-cause mortality or progression to the next more serious disease stage (n=996) (p>0.

 

This study confirms that SARS-CoV-2 infection patients receiving antibiotic treatment will not improve all-cause mortality or disease progression
.

This study confirms that SARS-CoV-2 infection patients receiving antibiotic treatment will not improve all-cause mortality or disease progression
.

 

 

Original source:

Maximilian J.

All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort.

Leave a message here